Navigation Links
Treatment with Paliperidone ER May Be Associated with Significantly Reduced Use of Mental Health Resources
Date:5/7/2008

Separate Analysis Suggests Paliperidone ER May Impact Employment Status

WASHINGTON, May 7 /PRNewswire-FirstCall/ -- Patients receiving paliperidone extended-release tablets (paliperidone ER) spent significantly fewer days in the hospital, had significantly fewer emergency room and psychiatric-related office visits, and fewer psychotherapy sessions, compared with the year before starting treatment, according to a new analysis of data presented at the 161st Annual Meeting of the American Psychiatric Association (APA) in Washington, D.C.(1)

In the analysis, researchers retrospectively reviewed the charts of 79 of the patients who had participated in any of three multi-center, double-blind, randomized six-week trials of paliperidone ER and placebo, and were then entered into a 12-month open-label extension (OLE) phase. The investigators compared the number of days a patient was hospitalized for psychiatric reasons in the 12 months before being screened for the trial (pre-period) with those in the 12-month OLE phase (post-period) following administration of the first dose of paliperidone ER.(a) Most of the patients (70.9 percent) had received prior antipsychotic medication during the pre-period.

The results showed that patients taking paliperidone ER used significantly fewer healthcare resources after starting on the medication than in the one-year period before entering the trials. Patients had an average of 12 fewer hospital days (P=0.002), 0.3 fewer emergency room visits (P=0.038), two fewer psychiatric-related office visits (P<0.001) and 0.4 fewer psychotherapy sessions (P=0.004).

An economic analysis showed that the average costs savings for the reduced resource use with paliperidone ER was $7,411 per person-year, based on current Federal Medicare per diem base rates and 2007 Medicare unit costs, taking into account psychiatric-related hospitalizations, emergency room visits, psychiatric-related clinic visits and psychotherapy.

<
'/>"/>
SOURCE Johnson & Johnson
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. BioTrends Releases Two Publications - TreatmentTrends(TM): Nephrologists and TreatmentTrends(TM): Renal Dietitians - Highlighting Market Trends for Renal Anemia, Hyperphosphatemia, and Secondary Hyperparathyroidism
2. Nucletron Announces Oncentra(R) Brachy* Treatment Planning Solution for Multimodality Environment
3. Wyeth and Progenics Receive Positive Opinion From European Committee for RELISTOR for the Treatment of Opioid-Induced Constipation in Advanced-Illness Patients
4. PEAT International Commissions Plasma-Based Waste Treatment Facility Designed Specifically for Onsite Waste Processing
5. Quest PharmaTech Receives Support from National Research Councils Industrial Research Assistance Program (NRC-IRAP) to develop Ultrasound Technology for the Treatment of Cancer
6. Atherotech VAP Cholesterol Test Meets Updated ADA, ACC Measurement and Treatment Guidelines for High Risk Patients
7. Sirion Therapeutics Preclinical Studies: Two New Potential Advances in Treatment of Retinal Diseases to be Presented at ARVO
8. Biotherm Announces a Unique Dermobiotic Three-Step Anti-Cellulite Slimming Treatment
9. Oncolytics Biotech Inc. Announces Gene Therapy Publication on Reovirus Treatment for Melanoma
10. Bionovo Identifies and Describes ER-beta Selective Compounds for the Treatment of Vaginal Dryness
11. Cephalon Announces European Commission Approval of EFFENTORA for the Treatment of Breakthrough Cancer Pain

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/20/2009)...-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasd...ircuit Court of Appeals reversed a U.S. District C... pursue all of its claims against The Lash Group, ...ial. CTI filed a complaint against The Lash Group...t for CTI,s product TRISENOX, in 2007 seeking $22....
(Date:11/19/2009)...stCall/ -- Omeros Corporation (Nasdaq: OMER ) tod...hird quarter ended September 30, 2009. For the thr...d a net loss of $3.9 million, or $1.34 per share, ...4 per share, for the same period in 2008. For the ...reported a net loss of $15.5 million, or $5.29 per...
(Date:11/19/2009)...ss., Nov. 19 Arlington Medical Res...leading driver of antibiotic selection in nosocomi...against gram-positive and gram-negative pathogens....socomial pneumonia, surveyed European physicians r...vide appropriate coverage against common pathogens...
(Date:11/19/2009)...d by latest award for revolutionary hearing aid. ...ber 16, 2009 -- Popular Science Magazine has named...m InSound Medical a winner of its coveted Best of ...p;   Chosen from thousands of entra...ng canal for up to four months while providing nat...
Breaking Biology Technology:Cell Therapeutics Wins Federal Appeal to Pursue $22.8 Million Claim Against The Lash Group 2Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 2Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 3Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 4Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 5Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 6Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 7Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 8Broad-Spectrum Antibacterial Activity is the Most Important Driver of Antibiotic Selection for Nosocomial Pneumonia In Europe 2Broad-Spectrum Antibacterial Activity is the Most Important Driver of Antibiotic Selection for Nosocomial Pneumonia In Europe 3Popular Science Awards Lyric &#8220;Invisible&#8221; Hearing Aid 2009 &#8220;Best of What's New&#8221; Award 2Popular Science Awards Lyric &#8220;Invisible&#8221; Hearing Aid 2009 &#8220;Best of What's New&#8221; Award 3
...d, Ph.D., Joins as Chief Executive Officer, MENLO...y, Inc. (FAB), a privately held biotechnology comp...ies B financing. Prior investor SV Life,Sciences (...lta Partners.,The proceeds from the financing will...synthesis technology to produce biologic drugs and...
...urg Regional Education Consortium Promoting Advanc..., Dec. 7 High school and,college students from th...anced technology careers and curriculum through a ...s and the commonwealth., At BioTech Day 2007, hos...chnology, Community and Economic Development Deput...
...D, Calif., Dec. 7 Ardea Biosciences,Inc. (Nasdaq:...ief Executive,Officer, Barry D. Quart, PharmD, wil...eatment" panel discussion at the RBC Capital Marke...er 12, 2007 at 1:30 p.m. (ET) at,the Westin Times ...t of the,presentation and panel discussion will be...
Other Biology Technology:Fundamental Applied Biology, Inc. Completes $21 Million Series B Financing 2Fundamental Applied Biology, Inc. Completes $21 Million Series B Financing 3Capital Area Biotechnology Partnership Receives $160,000 State Investment 2Ardea Biosciences to Participate in RBC Capital Markets 2007 Healthcare Conference 2Ardea Biosciences to Participate in RBC Capital Markets 2007 Healthcare Conference 3
(Date:11/23/2009)... available in German . , A bit of imaginati...be a bad thing. It could help to add data from are...ver, it must do so constructively. In order to inf...h more than just imagination, physicists at the Ma...d a theory of spatial perception called informatio...
(Date:11/22/2009)...ring South Korean scientists have succeeded in pro...ough bioengineering, rather than through the use o... research, which may now allow for the production ...d in two papers in the journal Biotechnology and ...sary. , Polymers are molecules found in everyda...
(Date:11/22/2009)...e Brain Research Centre, a partnership of the Univ... Vancouver Coastal Health Research Institute, have...which brain cells die following a stroke, as well ...ults of the study were recently published online i...brain cells continue to die even after blood flow ...
Breaking Biology News(10 mins):Visual assistance for cosmic blind spots 2Visual assistance for cosmic blind spots 3Visual assistance for cosmic blind spots 4Bioengineers succeed in producing plastic without the use of fossil fuels 2New understanding about mechanism for cell death after stroke leads to possible therapy 2KGI Establishes Post Baccalaureate Premedical Program 58514 1KGI Establishes Post Baccalaureate Premedical Program 58514 2Tianyin Pharmaceutical Co to Present at the Roth China Conference on October 14 at 12 3A30 pm ET 58511 1Tianyin Pharmaceutical Co to Present at the Roth China Conference on October 14 at 12 3A30 pm ET 58511 2Tianyin Pharmaceutical Co to Present at the Roth China Conference on October 14 at 12 3A30 pm ET 58511 3InteKrin Therapeutics Presents Positive INT131 Phase 2b Results at the 45th Annual European Association for the Study of Diabetes Meeting 14290 1InteKrin Therapeutics Presents Positive INT131 Phase 2b Results at the 45th Annual European Association for the Study of Diabetes Meeting 14290 2
...nywhere in the world soon could be made completely...rside geneticists, done in collaboration with scie...arch Institute in the Philippines. By gradually in...nce," a property that enables rice to survive extr...entially any variety of rice could be made to surv...
...fluenza vaccines may increase elderly patients, im... offering this vulnerable population additional pr...in the May 22 issue of Archives of Internal Medici...containing inactivated influenza virus have been a...ications, according to background information in t...
...f Minnesota researchers have discovered how a prev...r year in the United States overcomes the effects ...e of its chromosomes. , Candida albicans, a type...lly harmless. In otherwise healthy people, it can ...or thrush) that are easily treated. But in people ...
Other Biology News:Researchers develop flood-tolerant California rice 2Researchers develop flood-tolerant California rice 3High-dose flu vaccines appear to safely boost immunity in elderly 2U of M researchers discover genetic key to treating deadly fungal infections 2
ZOOM IPGRunner Mini-cell from Invitrogen
Rabbit Anti-XTP4 Polyclonal Antibody, Unconjugated from Abcam
Agarose, Type C from Calbiochem
Assay Diluent from BD Biosciences Pharmingen
Biology Products: